Amgen Inc.

AMGN-Q

NASDAQ:AMGN

241.55
0.08 (0.03%)
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm.
More at Wikipedia

Analysis and Opinions about AMGN-Q

Signal
Opinion
Expert
HOLD
HOLD
September 18, 2019
The biotech grandddaddy. A great company that's produced some fine drugs, but other technologies have taken the shine off this stock. New drugs haven't driven the stock up. It does trade at a reasonable 11x earnings. A decent stock and it's stable, but lacks the punch of its peers. It depends what happens in the US election in Nov. 2020 too.
Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
September 18, 2019
The biotech grandddaddy. A great company that's produced some fine drugs, but other technologies have taken the shine off this stock. New drugs haven't driven the stock up. It does trade at a reasonable 11x earnings. A decent stock and it's stable, but lacks the punch of its peers. It depends what happens in the US election in Nov. 2020 too.
PAST TOP PICK
PAST TOP PICK
July 17, 2019
(A Top Pick Jul 05/18, Up 3%) One of the world's largest biotech companies. They have 3-4 blockbuster drugs in the pipeline in phase 1 & 2. It's an under-owned stock. Enbrel, their largest-selling drug, is undergoing a parent review. If Amgen wins--which he thinks will happen--then there'll be a 12% stock boost; if not, it will fall 12%. Either way, after this review, Amgen is still worth buying.
Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
July 17, 2019
(A Top Pick Jul 05/18, Up 3%) One of the world's largest biotech companies. They have 3-4 blockbuster drugs in the pipeline in phase 1 & 2. It's an under-owned stock. Enbrel, their largest-selling drug, is undergoing a parent review. If Amgen wins--which he thinks will happen--then there'll be a 12% stock boost; if not, it will fall 12%. Either way, after this review, Amgen is still worth buying.
PARTIAL SELL
PARTIAL SELL
July 9, 2019
It has a nice head and shoulders, with a double-top at $210. It's now at a shoulder around $180. It needs to rise above this level. Continue to hold it or sell.
Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
July 9, 2019
It has a nice head and shoulders, with a double-top at $210. It's now at a shoulder around $180. It needs to rise above this level. Continue to hold it or sell.
COMMENT
COMMENT
May 23, 2019
Great product but the are matured. he prefers other Health Care names.
Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
May 23, 2019
Great product but the are matured. he prefers other Health Care names.
TOP PICK
TOP PICK
May 3, 2019
Large cap diversified biotech company. Seeing shorts because of a patent dispute. Diversified pipeline of drugs. Valuation is attractive. Buy this as a basket. Yield is 3.27%. (Analysts’ price target is $206.95)
Show full opinionHide full opinion
Large cap diversified biotech company. Seeing shorts because of a patent dispute. Diversified pipeline of drugs. Valuation is attractive. Buy this as a basket. Yield is 3.27%. (Analysts’ price target is $206.95)
WAIT
WAIT
April 30, 2019
It's been in a choppy uptrend since 2017, and is now consolidating. Lows are around $180 and now testing that area. If it breaks out, it would be positive. Otherwise, it's wait and see.
Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
April 30, 2019
It's been in a choppy uptrend since 2017, and is now consolidating. Lows are around $180 and now testing that area. If it breaks out, it would be positive. Otherwise, it's wait and see.
DON'T BUY
DON'T BUY
April 22, 2019
The grandaddy of the biotechs, a good solid holding, trading at 14x earnings. But it lacks a catalyst.
Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
April 22, 2019
The grandaddy of the biotechs, a good solid holding, trading at 14x earnings. But it lacks a catalyst.
PAST TOP PICK
PAST TOP PICK
December 3, 2018
(A Top Pick Jul 05/18, Up 10%) He held onto this over the summer, despite expecting autumnal volatility. It's a diversified biotech and big in bio-similars, so AMGN would benefit from an uptick here. It's reasonably priced.
Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
December 3, 2018
(A Top Pick Jul 05/18, Up 10%) He held onto this over the summer, despite expecting autumnal volatility. It's a diversified biotech and big in bio-similars, so AMGN would benefit from an uptick here. It's reasonably priced.
WAIT
WAIT
October 19, 2018

Had owned it for a number of years but sold it recently. The growth trajectory going forward was slowing. Still pretty cheap and great cash flow. For him to get back into this stock, it would have to be significantly lower.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
October 19, 2018

Had owned it for a number of years but sold it recently. The growth trajectory going forward was slowing. Still pretty cheap and great cash flow. For him to get back into this stock, it would have to be significantly lower.

TOP PICK
TOP PICK
July 5, 2018

One of the leading biotech firms. They have a number of new drugs that came out. Dividend yield of 2.8%. Market cap of $124 billion. (Analysts’ price target is $196.95)

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
July 5, 2018

One of the leading biotech firms. They have a number of new drugs that came out. Dividend yield of 2.8%. Market cap of $124 billion. (Analysts’ price target is $196.95)

COMMENT
COMMENT
November 2, 2017

Pharmaceutical stocks have had a much more difficult time because of the presidential election, a time when they usually fall. However, they've bounced back as much as they normally do. This is not expensive. Trading at about 14X earnings and pays a nice dividend yield. Has some really great drugs in their pipeline. It continues to outperform on an earnings basis. He really likes this.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
November 2, 2017

Pharmaceutical stocks have had a much more difficult time because of the presidential election, a time when they usually fall. However, they've bounced back as much as they normally do. This is not expensive. Trading at about 14X earnings and pays a nice dividend yield. Has some really great drugs in their pipeline. It continues to outperform on an earnings basis. He really likes this.

HOLD
HOLD
October 26, 2017

Sell?This company has a very high free cash flow yield and is very profitable. Have some drugs coming off patent, but biotech drugs generally survive the loss of patents because the drugs are hard to copy. Thinks you will be fine with this in the long run. 2.6% dividend yield.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
October 26, 2017

Sell?This company has a very high free cash flow yield and is very profitable. Have some drugs coming off patent, but biotech drugs generally survive the loss of patents because the drugs are hard to copy. Thinks you will be fine with this in the long run. 2.6% dividend yield.

HOLD
HOLD
October 10, 2017

Hold or Sell? Within biotech and picking a single name, this company would be the way to do it. They are more diversified. They’ve had a few good quarters in a row beating earnings, and are still only trading at 14-16 levels. Putting up pretty good growth. Now that we are more comfortable with interest rates not going to the moon, that takes off the risk, opening up the door to make this more investable.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
October 10, 2017

Hold or Sell? Within biotech and picking a single name, this company would be the way to do it. They are more diversified. They’ve had a few good quarters in a row beating earnings, and are still only trading at 14-16 levels. Putting up pretty good growth. Now that we are more comfortable with interest rates not going to the moon, that takes off the risk, opening up the door to make this more investable.

HOLD
HOLD
September 19, 2017

A fairly inexpensive stock from a valuation standpoint. One of the granddaddies of biotech. This is probably a good hold here. The whole biotech area is getting a bit of a bid under it. There has been more positive action within that whole sector.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
September 19, 2017

A fairly inexpensive stock from a valuation standpoint. One of the granddaddies of biotech. This is probably a good hold here. The whole biotech area is getting a bit of a bid under it. There has been more positive action within that whole sector.

HOLD
HOLD
September 14, 2017

They create drugs similar to other bio-similar drugs. The competitive threats in biologics are a little bit similar. They got approval this morning for a biologic drug. He would like to see them consolidate here.

Show full opinionHide full opinion
Amgen Inc. (AMGN-Q)
September 14, 2017

They create drugs similar to other bio-similar drugs. The competitive threats in biologics are a little bit similar. They got approval this morning for a biologic drug. He would like to see them consolidate here.

Showing 1 to 15 of 102 entries

Amgen Inc.(AMGN-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Amgen Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Amgen Inc.(AMGN-Q) Frequently Asked Questions

What is Amgen Inc. stock symbol?

Amgen Inc. is a American stock, trading under the symbol AMGN-Q on the NASDAQ (AMGN). It is usually referred to as NASDAQ:AMGN or AMGN-Q

Is Amgen Inc. a buy or a sell?

In the last year, 1 stock analyst published opinions about AMGN-Q. 0 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is HOLD. Read the latest stock experts' ratings for Amgen Inc..

Is Amgen Inc. a good investment or a top pick?

Amgen Inc. was recommended as a Top Pick by Gordon Reid on 2019-09-18. Read the latest stock experts ratings for Amgen Inc..

Why is Amgen Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Amgen Inc. worth watching?

1 stock analyst on Stockchase covered Amgen Inc. In the last year. It is a trending stock that is worth watching.

What is Amgen Inc. stock price?

On 2020-08-06, Amgen Inc. (AMGN-Q) stock closed at a price of $241.55.